Diffusion of Oral and Intravenous 400 mg Once-Daily Moxifloxacin into Lung Tissue at Pharmacokinetic Steady-State

Journal of Chemotherapy

Volumn 15, Issue 6, 2003, Pages 558-562

  Breilh, D ^a   Jougon, J ^a   Djabarouti, S ^a   Gordien, J B ^a   Xuereb, F ^a   Velly, J F ^a,b   Arvis, P ^c   Landreau, V ^c   Saux, M C ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Bayer Pharma   (France)

Author keywords

Antibiotics; Community acquired respiratory tract infection; Diffusion; Lung tissue; Moxifloxacin

Indexed keywords

ANTIINFECTIVE AGENT; MOXIFLOXACIN;

ARTICLE; BIOACCUMULATION; BLOOD ANALYSIS; BRONCHUS CANCER; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG EFFICACY; DRUG PENETRATION; HUMAN; HUMAN TISSUE; LUNG PARENCHYMA; LUNG SURGERY; MINIMUM INHIBITORY CONCENTRATION; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; STEADY STATE; TISSUE DISTRIBUTION;

EID: 1242317740     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.6.558     Document Type: Article

References (25)

1. Eicher HG, Müller M. Drug distribution-the forgotten relative of clinical pharmacokinetics. Clin Pharmacokinet 1998; 34: 95-99.
2. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995; 28: 143-160.
3. Drusano GL, Craig W. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 Suppl 3: 38-44.
4. Craig W. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microb Infect Dis 1993;12 Suppl. 1: S6-S8.
5. Dawson SJ, Reeves DS. Therapeutic monitoring, the concentration-effect relationship and impact on the clinical efficacy of antibiotic agents. J Chemother 1997; 9 Suppl 1: 84-92.
6. Rotschafer JC, Zabinski RA, Walker KJ. Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy 1992; 12: 64S-70S.
7. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992; 36: 1176-1180.
8. Lemoine T, Breilh D, Ducint D, Dubrez J, Jougon J, Velly JF, et al. Determination of moxifloxacin (BAY 12-8039) in plasma and lung tissue by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge. J Chrom B 2000; 742: 247-254.
9. Stass H, Kubitza D, Schüly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001; 40 Suppl. 1: 1-9.
10. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl. B: 83-90.
11. Ballow C, Lettieri J, Agarwal V et al. Absolute bioavailability of moxifloxacin. Clin Ther 1999; 21: 513-22.
12. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquire respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 2000; 20: 245-56.
13. Garcia-Rodriguez JA, Gomez-Garcia AC. The microbiology of moxifloxacin. Drugs Today 2000; 36: 215-227.
14. Boswell EJ, Andrews JM, Wise R, Dalhoff A. Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999; 43: 43-49.
15. Dalhoff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 1999; 43 Suppl. B: 51-59.
16. th ed. New York: Churchill Livingstone; 1995: 225-233.
17. nd ed (Hooper DC and Wolfson JS., eds), American Society for Microbiology, Washington DC. 1993: 259-271.
18. Honeybourne D. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Current opinion Pulm Med 1997; 3: 170-174.
19. Nix DE. Intrapulmonary concentrations of antimicrobial agents. Infect Dis Clin North Am 1998; 12: 631-646.
20. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest 1999; 17: 365-87.
21. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego CA. 1998. Abstract A29.
22. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1999; 44: 835-838.
23. Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther 1999; 21: 3-40.
24. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory quinolones". J Antimicrob Chemother 1999; 43 Suppl. B: 1-11.
25. Gehanno P, Darantière S, Dubreuil C, Chobaut JC, Bobin S, Pages JC et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 2002; 49: 821-826.